C4 Therapeutics, Inc.
A biopharmaceutical company developing targeted protein degradation medicines, a technology that harnesses the body's own protein-disposal machinery to destroy disease-causing proteins. Its lead programs target cancers and other serious diseases. The company was founded in 2015 as a spinout from Dana-Farber Cancer Institute, and its name reflects its focus on the "C4" family of E3 ligase enzymes that tag proteins for destruction.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 13G/APassive | 9.99% | 15.42M | Aug 14, 2026 |
| Weston Nichols | 13G/APassive | 9.99% | 15.42M | Aug 14, 2026 |
| RA Capital Management, L.P. | 13G/APassive | 9.9% | 11.38M | Aug 14, 2026 |
| Peter Kolchinsky | 13G/APassive | 9.9% | 11.38M | Aug 14, 2026 |
| Rajeev Shah | 13G/APassive | 9.9% | 11.38M | Aug 14, 2026 |
| RA Capital Healthcare Fund, L.P. | 13G/APassive | 9.9% | 11.38M | Aug 14, 2026 |
| Squadron Master Fund LP | 13G/APassive | 6.9% | 7.60M | Aug 14, 2026 |
| Squadron Capital Management LLC | 13G/APassive | 6.9% | 7.60M | Aug 14, 2026 |
| Matthew Sesterhenn | 13G/APassive | 6.9% | 7.60M | Aug 14, 2026 |
| William Blank | 13G/APassive | 6.9% | 7.60M | Aug 14, 2026 |